Floatz logo

VINCRISTINE SULFATE

Metastatic Malignant Uveal Melanoma

Spectrum Pharmaceuticals, IncSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Malignant Uveal Melanoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Spectrum Pharmaceuticals, Inc
Phase 2B

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →